Skip to content
Screener

Lantheus Holdings LNTH Reportable — Other Research And Development Expense

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — Other Research And Development Expense
$2.37M+3.2%
Dogwood Therapeutics logo
DWTXSingle Reportable — Other Research And Development Expense
$585.61K+33.4%
UroGen Pharma logo
URGNSingle Reportable — Other Research And Development Expense
$258K+119%
Celldex Therapeutics logo
CLDXSingle Reportable — Other Research And Development Expense
$6.14M+71.1%
Solid Biosciences Inc. logo
SLDBExternal Research And Development Other — Other Research And Development Expense
$1.98M-36.4%
TG Therapeutics logo
TGTXOther Research And Development Expense
$87.27M+218%

Other financials

Income statement

See full
Revenue$388.2M+2.7%
Gross profit$241.9M+0.4%
Operating income$100.2M+13.9%
Net income$75.0M-4.7%
EPS (diluted)$1.11-0.9%

Balance sheet

See full
Cash & equivalents$595.0M-14.7%
Total debt$626.8M+1.5%
Total equity$1.3B+12.4%
Total assets$2.4B+14.1%

Cash flow

See full
Operating cash flow$92.2M+5.9%
CapEx$2.3M-70.7%
Free cash flow$89.9M+13.5%

Valuation

See full
Market cap$6.63B+84.6%
Enterprise value$6.66B+89.7%
P/E24.1×+11.4×
P/S4.3×+1.9×

Profitability

See full
Gross margin60.1%-3.6pp
Operating margin19.4%-9.4pp
Net margin17.7%-0.9pp
FCF margin24.9%-6.6pp

Returns & leverage

See full
Return on equity22.2%-3.6pp
Debt / equity0.5×-0.1×
Current ratio3.1×-1.2×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The source filing: Lantheus Holdings’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336795
(in thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Program third-party research and development expenses$8,475$8,938$20,263$17,367
Other research and development expenses(1)29,72736,55157,31864,436
Total research and development expenses$38,202$45,489$77,581$81,803

Item 1. Financial Statements

FAQ

What is Lantheus Holdings's reportable — other research and development expense?
Lantheus Holdings (LNTH) reported reportable — other research and development expense of $29.73M in Q2 2026.
How has Lantheus Holdings's reportable — other research and development expense changed year-over-year?
Lantheus Holdings's reportable — other research and development expense decreased by 18.7% year-over-year, from $36.55M to $29.73M.
What is the long-term trend for Lantheus Holdings's reportable — other research and development expense?
Over 3 years (2022 to 2025), Lantheus Holdings's reportable — other research and development expense has grown at a -23.6% compound annual growth rate (CAGR), from $303.5M to $135.15M.
What does reportable — other research and development expense mean?
This metric captures all research and development expenditures within the reportable segment that are not classified as software development or acquired in-process research costs. It typically encompasses clinical trial expenses, laboratory supplies, personnel costs for scientific staff, and other operational outlays necessary for product innovation. Monitoring this figure provides insight into the baseline recurring investment required to sustain the company's pipeline of diagnostic and therapeutic products.

Ask your AI about Lantheus Holdings's reportable — other research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude